An exploratory, double-blind comparison of inspiratory capacity and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open label b.i.d. administration of formoterol

Trial Profile

An exploratory, double-blind comparison of inspiratory capacity and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open label b.i.d. administration of formoterol

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Indacaterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Sep 2007 Results presented at ERS 2007 (1083888)
    • 29 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top